2009-06-23 22:11:43 -
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today the completion of its previously reported public offering of 5,750,000 shares of common stock. The Company received net proceeds, after underwriting discounts and commissions and estimated expenses, of approximately $38.0 million.
Oppenheimer & Co. Inc. acted as the sole book-runner for the offering and Morgan Joseph & Co. Inc.
acted as co-manager.
The securities described above were offered by ImmunoGen pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering. The offering was made only by means of a prospectus, copies of which may be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 300 Madison Avenue, 5th Floor, New York, NY, 10017, by telephone at (212) 667-8563 or via email at
EquityProspectus@opco.com : mailto:EquityProspectus@opco.com .
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and linkage of potent cancer-cell killing agents (CKAs) to such antibodies.
The Company’s proprietary Targeted Antibody Payload TM (TAP) technology consists of ImmunoGen’s highly potent CKAs, which have been designed specifically for delivery by antibodies to cancer cells, and the Company’s engineered linkers, which direct the activation of the CKA inside a cancer cell. Compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s own programs and its collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.
ImmunoGen, Inc.Carol Hausner, 781-895-0600Executive
Director, Investor Relationsand Corporate Communications
info@immunogen.com : mailto:info@immunogen.com
